Biofrontera To Sell Photodynamic Therapy For Skin Diseases In Poland Via Supply Pact With Medac

Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG BFRA and Medac Gesellschaft für klinische Spezialpräparate mbH have signed an exclusive license and supply agreement for the marketing of both Ameluz and BF-RhodoLED in Poland.
The agreement has a term of 5 years commencing with the start of sales in Poland.
Under the terms of the agreement, Medac will make an immediate one-time upfront payment of €50,000, plus an additional one-time payment of €150,000 after the drug's reimbursement eligibility in Poland.
In 2011, Ameluz was approved for photodynamic therapy (PDT) of mild to moderate actinic keratoses, field cancerization, and superficial and nodular basal cell carcinomas.
Ameluz is approved for use in conventional PDT with red-light lamp BF-RhodoLED as well as for daylight PDT.
Price Action: BFRA shares are up 1.7% at $6.55 during the premarket session on the last check Friday.